The European Commission has awarded a grant worth 7.1 million euros to a group of European companies to develop a glucose blood level prediction tool based on Toumaz’s Sensium chip, a low power sensor interface for medical applications that we covered in July, 2006.
From EE Times:
The aim is to provide insulin dependent patients with much greater control in managing their condition. Current diabetes management techniques are restricted to the analysis of blood glucose history, with almost no ability to predict what blood glucose levels might be in several hours’ time.
The device will leverage sophisticated analysis of physiological inputs from non-intrusive body-worn wireless monitors based on the Sensium platform. This means the DIAdvisor will be capable of wirelessly connecting and providing information and trend data directly to healthcare providers, to enable further therapy improvements and treatment cost reduction.
Prediction of blood glucose levels will come from glucose measurements, insulin delivery data and specific patient parameters, to allow patients at any time to actively and accurately predict their short-term blood glucose outlook.
Toumaz’s role in the project will be to implement the DIAdvisor hardware and software platform, leveraging its intelligent data acquisition platform and networking infrastructure to enable multiple vital signs measurements from monitors to be taken and merged with manually entered ‘spot’ measurements (such as food intake), providing the key data for the creation of physiological mathematical modeling, control and prediction algorithms.
More at EE Times…